NASDAQ · Medical - Devices
BRKR (BRKR) Stock
$62.91
+4.76%
NASDAQ: BRKR
Healthcare
Valuation
Financials & Margins
Annual Financials (USD)
Balance Sheet (USD)
Latest News
Bruker Acquires Noscendo's Disqver Clinical Metagenomics Platform
MT Newswires · Jul 15, 2026
Bruker Expands Infection Detection Portfolio with Acquisition of Metagenomic mNGS DISQVER® Platform for Pathogenic Microorganisms in Blood
Business Wire · Jul 15, 2026
BRKR: Raising target price to $63.00
Argus Research · Jul 15, 2026
3 Cash-Producing Stocks We’re Skeptical Of
StockStory · Jul 14, 2026
BofA Securities Adjusts Bruker Price Target to $70 From $65
MT Newswires · Jul 13, 2026
Cash Flow (USD)
Valuation & Return Ratios
Ownership
Insiders Held26.96%
Institutions Held92.85%
Institutions Float Held127.12%
Peer Comparison
About BRKR
BRKR is led by CEO Frank H. Laukien, employs 11,085 people, headquartered in Billerica, US, publicly traded since 2000.
BRKR stock trades at $62.91 with a market capitalization of $9.58B. The stock is valued at a price-to-earnings (P/E) ratio of 23.24, price-to-book of 3.52, price-to-sales of 2.49. Over the past 52 weeks the stock has ranged between $28.53 and $64.54, and currently trades 2.5% below its 52-week high. It pays a dividend yielding 0.35%.
On profitability, BRKR generates a return on equity (ROE) of -0.43%, return on capital employed of 9.40%, an operating margin of 5.89%, a net profit margin of -0.34%.